GWM
RXST icon

Geneos Wealth Management’s RxSight RXST Stock Holding History

Geneos Wealth Management’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17
Closed -$584 – 3157
2024
Q4 		$584 Sell
17
-2
-11% -$90 ﹤0.01% 2862
2024
Q3 		$939 Buy
+19
New +$973 ﹤0.01% 2461

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Geneos Wealth Management's RXST Position: Q1 2025 in Review

Geneos Wealth Management sold out of RxSight (RXST) in Q1 2025, closing a stake of 17 shares — an estimated $584 sold.

Geneos Wealth Management first reported a position in RXST in Q3 2024 and held it in 2 quarters. The position peaked at $939 in Q3 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

  • Geneos Wealth Management reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 17 RxSight shares in Q1 2025, an estimated $584.
  • Geneos Wealth Management first reported a position in RxSight in Q3 2024 and held it in 2 quarters.
  • Geneos Wealth Management's RxSight position peaked at $939 in Q3 2024.
  • 192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on Geneos Wealth Management's 13F filing for Q1 2025, filed 8 May 2025.